Is AstraZeneca plc a strong buy after Q3 results?

Is AstraZeneca plc (LON: AZN) still on course for a recovery?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The last few years have been incredibly challenging for AstraZeneca (LSE: AZN). The company has suffered major falls in its earnings due to the loss of patents on key drugs. Generic competition has caused its earnings per share to drop by 37% between 2012 and 2016, with further falls expected in the current financial year.

However, following investment in its pipeline in recent years, investors have become increasingly optimistic about its prospects. After a third quarter update on Thursday, is there still cause for optimism regarding the company’s future?

Improving performance

Encouragingly, AstraZeneca has reported that the impact from the loss of exclusivity on its products is starting to recede. Sales in the quarter declined by just 2% at constant currency, and this shows that its strategy is working as planned. Alongside investment in its pipeline, there have been major cost cuts which continue to lessen the impact of the sales decline on its bottom line. For example, research and development costs moved 1% lower at constant currency, while its operating costs moved 11% lower.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

The result of this performance is expected to be a core earnings per share figure for the full year which is at the favourable end of guidance. This means that a low-teens percentage fall in earnings is on the cards for this year, which may help to boost investor sentiment in the short run.

Improving outlook

As mentioned, the company is investing heavily in its product pipeline. This has only been possible because of the strong balance sheet and cash flow of the business, and it is set to deliver positive earnings growth next year. While a rise of just 1% may be forecast for 2018, more earnings growth could be ahead as the impact of a loss of patents continues to recede and it is replaced with strong growth in the areas of the business in which it has invested in prior years.

With an improving outlook, it is perhaps unsurprising that AstraZeneca trades on a price-to-earnings (P/E) ratio of 17.8. This appears to be fair value for a company which has the potential to increase its profitability at a brisk pace in future. Furthermore, at its current price level it has a dividend yield of 4.2% from a shareholder payout which is covered 1.3 times by profit. This suggests that its income prospects are also bright.

Investment potential

As well as its capital growth and income prospects, AstraZeneca also has defensive appeal. It is less highly correlated to the performance of the wider economy than many of its FTSE 100 index peers. This could provide its investors with greater stability and resilience than they may be able to obtain in most stocks. As such, with its third quarter results showing continued improvements in its financial performance, now could be the right time to buy it for the long run.

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »